Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Impax Laboratories, Inc. v. Turing Pharmaceuticals AG
Case Number:
1:16-cv-03241
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
July 15, 2016
NY Judge Looks To Trim Impax AIDS Drug Suit Against Turing
A Manhattan federal judge said Friday he is inclined to cut a claim of unjust enrichment from Impax Laboratories' $30 million breach of contract case against Turing Pharmaceuticals, whose ex-leader Martin Shkreli jacked up the price of AIDS drug Daraprim, as the companies tangle over higher Medicaid costs tied to the infamous price hike.
-
May 19, 2016
Judge Says Turing Concedes Liability In Impax AIDS Drug Row
A Manhattan federal judge declined Wednesday to block Turing Pharmaceuticals AG from selling AIDS drug Daraprim featuring the label of Impax Laboratories Inc. per a distribution contract but said Turing, whose ex-leader Martin Shkreli famously jacked up price of the drug, owes for higher Medicaid reimbursement costs tied to the price hike.
-
May 02, 2016
Impax Sues Ex-Shkreli Co. For $20M In Daraprim Dispute
Impax Laboratories Inc. in New York federal court on Monday sued Turing Pharmaceuticals AG, the drugmaker previously led by Martin Shkreli, for $20 million, saying that it flouted contractual terms after buying the rights to anti-parasite drug Daraprim and jacking up the product's price by 5,000 percent.